IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

LIGORIO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.623
AS - Asia 1.451
NA - Nord America 1.353
SA - Sud America 117
AF - Africa 44
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.597
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.307
DE - Germania 672
IT - Italia 462
CN - Cina 423
SG - Singapore 405
HK - Hong Kong 163
BD - Bangladesh 126
BR - Brasile 88
IN - India 84
VN - Vietnam 81
NL - Olanda 80
FR - Francia 75
RU - Federazione Russa 69
GB - Regno Unito 65
SE - Svezia 60
FI - Finlandia 45
JP - Giappone 34
CA - Canada 27
KR - Corea 25
TR - Turchia 25
CI - Costa d'Avorio 22
IE - Irlanda 22
ID - Indonesia 16
PL - Polonia 14
DK - Danimarca 11
PH - Filippine 10
MX - Messico 9
RO - Romania 9
TW - Taiwan 9
NP - Nepal 8
UZ - Uzbekistan 8
ZA - Sudafrica 8
AR - Argentina 7
CO - Colombia 7
ES - Italia 7
SA - Arabia Saudita 7
AT - Austria 5
BE - Belgio 5
EG - Egitto 5
AU - Australia 4
CL - Cile 4
CZ - Repubblica Ceca 4
IQ - Iraq 4
CH - Svizzera 3
EC - Ecuador 3
HU - Ungheria 3
MY - Malesia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
TT - Trinidad e Tobago 3
UA - Ucraina 3
AP - ???statistics.table.value.countryCode.AP??? 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
TN - Tunisia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MV - Maldive 1
NI - Nicaragua 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SC - Seychelles 1
SV - El Salvador 1
TH - Thailandia 1
TM - Turkmenistan 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 4.597
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 619
Ashburn 217
Singapore 202
San Jose 137
Hong Kong 135
Milan 124
Dallas 99
Hefei 83
Council Bluffs 70
Santa Clara 69
Beijing 62
Los Angeles 52
Chandler 45
New York 33
Boardman 31
Helsinki 30
Bengaluru 29
Fairfield 29
Ho Chi Minh City 24
Abidjan 22
Dublin 22
Lauterbourg 21
Moscow 21
Southend 21
Rome 20
Hanoi 19
Tokyo 18
Guangzhou 17
Naples 17
Hyderabad 16
Cambridge 15
Houston 15
Buffalo 14
Jakarta 14
Amsterdam 13
Wilmington 13
Nuremberg 12
Shenzhen 12
Cangzhou 11
Düsseldorf 11
Istanbul 11
Munich 11
Seattle 11
London 10
Montreal 10
Orem 10
Seoul 10
Shanghai 10
Stockholm 10
Bucharest 9
Dong-gu 9
Lappeenranta 9
São Paulo 9
Atlanta 8
Denver 8
Fuzhou 8
Genoa 8
Hangzhou 8
Manchester 8
Princeton 8
Chicago 7
Phoenix 7
Redwood City 7
Salt Lake City 7
Shenyang 7
Tashkent 7
Bologna 6
Chennai 6
Florence 6
Paris 6
Woodbridge 6
Berlin 5
Elk Grove Village 5
Iwasakichō 5
Modena 5
Mumbai 5
New Delhi 5
Padua 5
Pessac 5
Philadelphia 5
Taipei 5
Turku 5
Warsaw 5
Bari 4
Bochum 4
Boston 4
Cairo 4
Dearborn 4
Dhaka 4
Johannesburg 4
Juiz de Fora 4
McAllen 4
Medellín 4
Memphis 4
Nanjing 4
Palermo 4
Piscataway 4
Poznan 4
San Diego 4
San Rafael 4
Totale 2.819
Salva come PNG Salva come JPEG
Nome #
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 526
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab 330
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer 307
Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence 251
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 225
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial 224
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients 222
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin 193
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 193
Wave climate at shallow waters along the Abu Dhabi coast 192
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 183
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 181
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 178
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 172
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 164
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report 163
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer 124
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis 121
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis 116
HER2 signaling and breast cancer stem cells: the bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness 108
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications 107
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications 107
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2 81
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 75
Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer 75
Fasting-mimicking diet plus chemotherapy in breast cancer treatment 72
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to Abemaciclib 17
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study 11
null 3
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2 1
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Totale 4.723
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.251
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.251
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126 0 0 0 0 0 0 0 0 0 0 0 26
2021/2022201 24 25 15 18 13 13 7 18 25 14 9 20
2022/2023214 17 24 14 10 26 47 9 19 23 1 21 3
2023/2024630 22 16 11 16 54 32 101 80 36 77 96 89
2024/20251.132 72 93 86 84 47 43 77 116 80 116 101 217
2025/20262.422 233 200 228 161 133 95 250 100 298 235 271 218
Totale 4.723